Download PDF
Horm Metab Res 2018; 50(04): 290-295
DOI: 10.1055/s-0044-101144
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children

Christina Tatsi
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
,
Meg Keil
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
,
Charalampos Lyssikatos
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
,
Elena Belyavskaya
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
,
Constantine A. Stratakis
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
,
Maya B. Lodish
1   Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
› Author Affiliations
Further Information

Publication History

received 01 December 2017

accepted 10 January 2018

Publication Date:
19 February 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Glucocorticoids are widely used for immunosuppression in autoimmune diseases. After the resolution of hypercortisolemia, the immune system recovers allowing for autoimmune diseases to manifest. Here we investigated the presence of autoimmune and related diseases that developed after cure of endogenous Cushing syndrome (CS) in children. We identified 129 children who were diagnosed and successfully treated for endogenous CS at the National Institutes of Health from 1997 until 2017, and who were followed for at least 6 months after treatment. We performed a retrospective chart review analysis to identify the presence of autoimmune or related diseases after cure. Ten children were diagnosed with a new autoimmune or related disorder after resolution of hypercortisolemia. This results in a frequency of 7.8% of our pediatric CS population. The identified patients had a shorter duration of hypercortisolemia prior to diagnosis, but did not otherwise differ from the remaining patients. The various identified diseases were: celiac disease (n=1), psoriasis (n=1), Hashimoto thyroiditis (n=1), Graves disease (n=1), optic neuritis (n=2), skin hypopigmented lesions/vitiligo (n=2), allergic rhinitis/asthma (n=1), and neuropathy responding to glucocorticoid treatment (n=1). The reported time between the treatment of CS and diagnosis of autoimmune disorder ranged from 6 to 19 months. The presence of autoimmune or related diseases might be masked by the hypercortisolemic state in endogenous CS. After resolution of hypercortisolemia, the presentation of new autoimmune diseases or recurrence of previously known autoimmune conditions should be considered when concerning symptoms arise.

Key words

hypercortisolemia - immune system - thyroiditis - children
 

  • References

  • 1 Pufall MA.. Glucocorticoids and Cancer. Adv Exp Med Biol 2015; 872: 315-333
    PubMedGoogle Scholar
  • 2 Oppong E, Cato AC. Effects of Glucocorticoids in the Immune System. Adv Exp Med Biol 2015; 872: 217-233
    PubMedGoogle Scholar
  • 3 Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F. Glucocorticoids. Best Pract Res Clin Rheumatol 2011; 25: 891-900
    CrossrefPubMedGoogle Scholar
  • 4 Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85: 42-47
    PubMedGoogle Scholar
  • 5 Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013; 24: 109-119
    CrossrefPubMedGoogle Scholar
  • 6 Colao A, Pivonello R, Faggiano A, Filippella M, Ferone D, Di Somma C, Cerbone G, Marzullo P, Fenzi G, Lombardi G. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2000; 53: 13-19
    CrossrefPubMedGoogle Scholar
  • 7 da Mota F, Murray C, Ezzat S. Overt immune dysfunction after Cushing's syndrome remission: A consecutive case series and review of the literature. J Clin Endocrinol Metab 2011; 96: E1670-E1674
    CrossrefPubMedGoogle Scholar
  • 8 Stratakis CA, Mastorakos G, Magiakou MA, Papavasiliou E, Oldfield EH, Chrousos GP. Thyroid function in children with Cushing's disease before and after transsphenoidal surgery. J Pediatr 1997; 131: 905-909
    CrossrefPubMedGoogle Scholar
  • 9 Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH. Pseudotumor cerebri after surgical remission of Cushing's disease. J Clin Endocrinol Metab 2010; 95: 1528-1532
    CrossrefPubMedGoogle Scholar
  • 10 Stratakis CA. Diagnosis and clinical genetics of cushing syndrome in pediatrics. Endocrinol Metab Clin North Am 2016; 45: 311-328
    CrossrefPubMedGoogle Scholar
  • 11 Yakushiji F, Kita M, Hiroi N, Ueshiba H, Monma I, Miyachi Y. Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing's syndrome. Endocr J 1995; 42: 219-223
    CrossrefPubMedGoogle Scholar
  • 12 Noguchi Y, Tamai H, Fujisawa K, Nagano J, Mukuta T, Komaki G, Masubayashi S, Kubo C, Torisu M, Nakagaki H, Imayama S. Systemic lupus erythematosus after pituitary adenomectomy in a patient with Cushing's disease. Clin Endocrinol (Oxf) 1998; 48: 670-672
    PubMedGoogle Scholar
  • 13 Candrina R, Di Stefano O. Exacerbation of celiac disease after cure of Cushing's disease. Am J Med 1993; 95: 341
    CrossrefPubMedGoogle Scholar
  • 14 Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63: 60-72
    CrossrefPubMedGoogle Scholar
  • 15 Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: Unexpected targets and mechanisms. Mol Endocrinol 2011; 25: 1075-1086
    CrossrefPubMedGoogle Scholar
  • 16 Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets 2011; 12: 556-562
    CrossrefPubMedGoogle Scholar
  • 17 Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154: 4719-4725
    PubMedGoogle Scholar
  • 18 Mussig K, Gallwitz B. Haring HU, Seif FJ. Manifestation of thyroid autoimmunity in patients successfully treated for hypercortisolism. Clin Endocrinol (Oxf) 2004; 61: 284
    CrossrefPubMedGoogle Scholar
  • 19 Kasperlik-Zatuska AA, Zgliczynski W. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2001; 54: 411 author's reply 411
    PubMedGoogle Scholar
  • 20 Liu Y, Li C, Zhao W, Wang Y. Hashimoto's thyroiditis is an important risk factor of papillary thyroid microcarcinoma in younger adults. Horm Metab Res 2017; 49: 732-738
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Veit F, Graf D, Momberger S, Helmich-Kapp B, Ruschenburg I, Peters A, Kussmann J, Saeger W, Schmidt KW, Toetsch M, Nestler K, Mann K. Papillary thyroid cancer and coexisting autoimmune thyroiditis. Horm Metab Res 2017; 49: 869-872
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, Zhou H, Wang E, Tsang JS, Nussenblatt R. Consortium CHI . Effects of systemically administered hydrocortisone on the human immunome. Sci Rep 2016; 6: 23002
    CrossrefPubMedGoogle Scholar
  • 23 Choung RS, Unalp-Arida A, Ruhl CE, Brantner TL, Everhart JE, Murray JA. Less hidden celiac disease but increased gluten avoidance without a diagnosis in the united states: Findings from the national health and nutrition examination surveys from 2009 to 2014. Mayo Clin Proc 2016 pii: S0025-6196(16)30634-6. doi: 10.1016/j.mayocp.2016.10.012, Dec 5 [Epub ahead of print]
    PubMed
  • 24 Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, Papadopoulos NG, Rotiroti G, Scadding G, Timmermans F, Valovirta E. Paediatric rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013; 68: 1102-1116
    PubMedGoogle Scholar
  • 25 Milligan KL, Matsui E, Sharma H. Asthma in urban children: Epidemiology, environmental risk factors, and the public health domain. Curr Allergy Asthma Rep 2016; 16: 33
    CrossrefPubMedGoogle Scholar
  • 26 Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol 2017; 18: 797-811
    CrossrefPubMedGoogle Scholar
  • 27 Phiske MM. Vitiligo in Children: A Birds Eye View. Curr Pediatr Rev 2016; 12: 55-66
    CrossrefPubMedGoogle Scholar
  • 28 Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents: A review. JAMA Pediatr 2016; 170: 1008-1019
    CrossrefPubMedGoogle Scholar
  • 29 Yeh EA, Graves JS, Benson LA, Wassmer E, Waldman A. Pediatric optic neuritis. Neurology 2016; 87: S53-S58
    CrossrefPubMedGoogle Scholar